FDA Ends Emergency Use for One COVID Test
Published Date: 8/15/2025
Notice
Summary
The FDA is ending the emergency approval for LumiraDx’s COVID-19 test because the company asked them to. This means the test can no longer be used for quick COVID-19 diagnosis. If you use or sell this test, you’ll need to stop soon, but no extra costs or penalties are mentioned.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
LumiraDx COVID Test Authorization Revoked
If you use or sell the LumiraDx SARS CoV-2 RNA STAR Complete test, you must stop: the FDA revoked its Emergency Use Authorization at the company's request, so that test can no longer be used for quick COVID-19 diagnosis.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2025-15553 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Mine, Development, and Mineral Exploration Supplement
The U.S. Geological Survey is asking to keep collecting info about mining and mineral exploration. This affects companies and folks digging for minerals, making sure they provide updated details without extra hassle. The review helps keep paperwork smooth and on time, with no new fees or delays expected.
Next: 2025-15558 — Office of the Director, National Institutes of Health; Amended Notice of Meeting
The NIH Council of Councils meeting on September 11-12, 2025, has switched to fully virtual and moved to a new online location. The start and end times on September 12 have shifted slightly, and part of the meeting will be closed to the public. This update affects attendees and anyone following NIH decisions but doesn’t change any funding or deadlines.